ClinicalTrials.gg
CompletedNCT00727987Updated May 23, 2013

A Safety and Efficacy Study of Golimumab (CNTO 148) in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

A Phase 3 interventional study of CNTO 148 and Placebo in Rheumatoid Arthritis, sponsored by Janssen Pharmaceutical K.K.. Completed at 69 sites in Japan. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2013-05-23.

Sponsored by Janssen Pharmaceutical K.K. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
269
Allocation
Randomized
Ages
20 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.

Enrollment
37th of 113
269 · median 130
Started
2008
with 6 others
Phase 3
47 of 113
1 open now
Registered
30th of 113
by date

Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 37th largest by enrollment, is one of 7 that started in 2008, is one of 47 in phase 3, and was the 30th registered.

Arthritis, Rheumatoid

3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 20 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing methotrexate in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and effectiveness of golimumab in patients with active rheumatoid arthritis despite Methotrexate therapy. Another objective is to evaluate the pharmacokinetics of golimumab.

Read the detailed description

This clinical study is scheduled to be performed for the purpose of evaluating the safety and effectiveness of golimumab (CNTO148) administered in combination with stable dose (6-8mg/week) of methotrexate (MTX) to patients with rheumatoid arthritis (RA). CNTO148 50 mg group: CNTO148 50 mg SC injections every 4 weeks from the first administration until week 152. If early escape, 100 mg SC injections every 4 weeks from week 16 until week 152. CNTO148 100 mg group: CNTO148 100 mg SC injections every 4 weeks from the first administration until week 152 whether early escape or not Placebo group: Placebo SC injections every 4 weeks from the first administration until week 20 and then CNTO148 50mg SC injections every 4 weeks from week 16 until week 152

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid arthritis
  • Fully Human anti-TNFa monoclonal antibody
  • CNTO148
  • Golimumab
04

Who can participate

Ages eligible
20 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with rheumatoid arthritis at least 3 months prior to registration and who are definitely identified as having rheumatoid arthritis, at the time of , according to the criteria for classification established by the American College of Rheumatology (1987)
  • Patients in whom MTX therapy (>= 6 mg/week) was started more than 3 months before the first administration and who have been treated with MTX at a stable dose (6-8 mg/week) for at least 4 weeks before the first administration
  • Patients having at least 4 swollen joints and at least 4 tender joints at the time of registration and immediately before the first administration.

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of to human immunoglobulin proteins or other ingredients of golimumab
  • Patients who have previously experienced or are suffering from any of the following diseases: (i) Collagen diseases other than rheumatoid arthritis, (ii) Latent or active granulomatous infections such as histoplasmosis and coccidioidomycosis, (iii) Felty syndrome, etc
  • Patients with a severe, advanced, or poorly controlled disease in any of the kidney, liver, blood, gastrointestinal system, endocrine system, lung, heart, nervous system, psychiatric system, and brain.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
269 participants (actual)

Study arms

  • Experimental
    CNTO 148 50 mg + methotrexate

    Drug: CNTO 148 · Drug: Methotrexate (MTX)

  • Experimental
    CNTO 148 100 mg + methotrexate

    Drug: Methotrexate (MTX)

  • Placebo comparator
    Placebo + methotrexate

    Drug: Placebo · Drug: Methotrexate (MTX)

Interventions

  • 50 mg or 100 mg given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 152.

    Also known as: Golimumab

  • DrugPlacebo

    Placebo identical in appearance to CNTO 148 given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 24.

  • 6 mg/week to 8 mg/week taken orally (by mouth) from at least 4 weeks before the initial investigational treatment to the completion of assessment at Week 52.

06

What researchers measure

Primary outcomes

  1. ACR 20% response

    Time frame: Week 14

Secondary outcomes

  1. ACR 50% response, ACR 70% response, ACR 90% response, Changes from the pretreatment values in the DAS (Disease Activity Score) 28, and the HAQ (Health assessment questionnaire)

    Time frame: Week 14

07

Study locations

69 sites
  • Asahikawa, Japan
  • Asahi, Japan
  • Azumino, Japan
  • Chiba, Japan
  • Fukui, Japan
  • Fukuoka, Japan
  • Fukushima, Japan
  • Gifu, Japan
  • Goshogawara, Japan
  • Hachioji, Japan
  • Hamamatsu, Japan
  • Higashi-Hiroshima, Japan
  • Hiki, Japan
  • Hiroshima, Japan
  • Hitachi, Japan
  • Iruma, Japan
  • Izumisano, Japan
  • Izumo, Japan
  • Kamakura, Japan
  • Kato, Japan
  • Kawachi-Nagano, Japan
  • Kawagoe, Japan
  • Kawasaki, Japan
  • Kita-Gun, Japan
  • Kitakyushu, Japan
  • Kitamoto, Japan
  • Kobe, Japan
  • Kumamoto, Japan
  • Kyoto, Japan
  • Matsue, Japan
  • Matsumoto, Japan
  • Matsuyama, Japan
  • Nagano, Japan
  • Nagasaki, Japan
  • Nagoya, Japan
  • Narashino, Japan
  • Nishinomiya, Japan
  • Ohta-Ku, Japan
  • Oita, Japan
  • Osaka-City, Japan
  • Osaka, Japan
  • Osaki, Japan
  • Sagamihara, Japan
  • Saitama, Japan
  • Sapporo, Japan
  • Sasebo, Japan
  • Sendai N/A, Japan
  • Sendai, Japan
  • Shimotsuga, Japan
  • Shimotsuke, Japan
  • Shinjuku-Ku, Japan
  • Shinjuku, Japan
  • Shizuoka, Japan
  • Suita, Japan
  • Tokorozawa, Japan
  • Tokushima N/A, Japan
  • Tokyo N/A, Japan
  • Tokyo, Japan
  • Toshima-Ku, Japan
  • Toyama, Japan
  • Toyoake, Japan
  • Toyohashi, Japan
  • Tsukuba, Japan
  • Tsukubo, Japan
  • Tsu, Japan
  • Ube, Japan
  • Yokohama N/A, Japan
  • Yokohama, Japan
  • Yufu, Japan
08

References and documents

Publications

  • Tanaka Y, Harigai M, Takeuchi T, Yamanaka H, Ishiguro N, Yamamoto K, Miyasaka N, Koike T, Kanazawa M, Oba T, Yoshinari T, Baker D; GO-FORTH Study Group. Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. Ann Rheum Dis. 2012 Jun;71(6):817-24. doi: 10.1136/ard.2011.200317. Epub 2011 Nov 25. PubMed 22121129 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2008
First posted
Aug 5, 2008
Start
May 2008
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Last update
May 23, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00727987
Responsible party
Sponsor
First posted
Aug 5, 2008
Start date
May 2008
Primary completion
Dec 2011
Completion
Dec 2011
Last update
May 23, 2013

Study contacts

Janssen Pharmaceutical K.K. Clinical Trial
study director · Janssen Pharmaceutical K.K.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methotrexate

Start the discussion